دورية أكاديمية
أعرض في EDS

Risk of tuberculosis among Alabama children and adolescents treated with tumor necrosis factor inhibitors: a retrospective study.

التفاصيل البيبلوغرافية
العنوان: Risk of tuberculosis among Alabama children and adolescents treated with tumor necrosis factor inhibitors: a retrospective study.
المؤلفون: Stoll ML; Department of Pediatrics, University of Alabama at Birmingham, CPP N 210M / 1600 7th Avenue South, Birmingham, AL, 35233, USA. mstoll@peds.uab.edu., Grubbs JA; Department of Medicine, University of South Carolina School of Medicine, Medical Park, Suite 420, Columbia, SC, 29203, USA., Beukelman T; Department of Pediatrics, University of Alabama at Birmingham, CPP N 210M / 1600 7th Avenue South, Birmingham, AL, 35233, USA., Mannion ML; Department of Pediatrics, University of Alabama at Birmingham, CPP N 210M / 1600 7th Avenue South, Birmingham, AL, 35233, USA., Jester TW; Department of Pediatrics, University of Alabama at Birmingham, CPP N 210M / 1600 7th Avenue South, Birmingham, AL, 35233, USA., Cron RQ; Department of Pediatrics, University of Alabama at Birmingham, CPP N 210M / 1600 7th Avenue South, Birmingham, AL, 35233, USA., Crain MJ; Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL, USA.
المصدر: Pediatric rheumatology online journal [Pediatr Rheumatol Online J] 2017 Nov 09; Vol. 15 (1), pp. 79. Date of Electronic Publication: 2017 Nov 09.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101248897 Publication Model: Electronic Cited Medium: Internet ISSN: 1546-0096 (Electronic) Linking ISSN: 15460096 NLM ISO Abbreviation: Pediatr Rheumatol Online J Subsets: MEDLINE
أسماء مطبوعة: Publication: 2007- : [London] : BioMed Central
Original Publication: [Chicago, Ill. : University of Chicago, 2003]-
مواضيع طبية MeSH: Antirheumatic Agents/*adverse effects , Tuberculosis/*epidemiology , Tumor Necrosis Factor-alpha/*antagonists & inhibitors, Adolescent ; Alabama/epidemiology ; Antirheumatic Agents/therapeutic use ; Child ; Female ; Humans ; Incidence ; Male ; Retrospective Studies ; Risk Assessment ; Tuberculosis/etiology
مستخلص: Background: Tumor Necrosis Factor inhibitors (TNFi) have dramatically improved the outlook for patients with inflammatory arthritides and bowel disease (IBD), but are associated with increased infection risks, including tuberculosis (TB). Pediatric inflammatory diseases are uncommon, and the risk of TB in children taking TNFi remains unclear. The objective of this study was to report the incidence of TB disease among TNFi recipients at a single pediatric medical center serving most of Alabama compared to that of the general population of Alabama children.
Methods: Instances of TNFi usage among patients under age 20 years from July 1, 2007 through April 17, 2015 were captured from electronic health records at Children's of Alabama (CoA), which has the only pediatric rheumatology clinic in Alabama, and where a substantial number of children in Alabama with inflammatory bowel disease receive care., and reports of TB cases were obtained from the Alabama Department of Public Health (ADPH). Incidence was expressed as TB cases/10,000 person-years, using population estimates from the Alabama Center for Health Statistics.
Results: 1033 Alabama patients at CoA who were residents of Alabama were identified who received TNFi for a total of 1564 person-years. One adolescent on TNFi developed severe extrapulmonary TB (incidence density = 6.4 per 10,000; 95% CI 0.9-45.4 per 10,000). Sixty-three cases occurred in persons not on TNFi (incidence density = 0.064 per 10,000; 95% CI 0.050-0.082 per 10,000).
Conclusions: One case of TB disease among TNFi-exposed children was identified for 1564 person-years in Alabama residents. Although rare, this is higher than expected relative to the general rate of TB in Alabama. Thus, continued diagnostic vigilance for TB in children taking TNFi is required.
Trial Registration Number: Not applicable.
References: Arthritis Rheum. 2013 Oct;65(10):2499-512. (PMID: 24092554)
Arthritis Res Ther. 2012 Jun 08;14(3):213. (PMID: 22682420)
Am J Orthod Dentofacial Orthop. 1997 Apr;111(4):391-400. (PMID: 9109584)
J Clin Pediatr Dent. 2009 Summer;33(4):351-7. (PMID: 19725245)
Am J Gastroenterol. 2012 Sep;107(9):1409-22. (PMID: 22890223)
J Pediatr Gastroenterol Nutr. 2012 Jul;55(1):93-108. (PMID: 22516861)
Pediatr Rheumatol Online J. 2014 Apr 23;12:13. (PMID: 24782683)
Arthritis Rheum. 2005 Jul;52(7):1986-92. (PMID: 15986370)
Ann Rheum Dis. 2004 Jan;63(1):102-3. (PMID: 14672902)
Arthritis Care Res. 1996 Apr;9(2):126-32. (PMID: 8970271)
Pediatr Infect Dis J. 2014 Aug;33(8):885-8. (PMID: 24642517)
Arthritis Rheumatol. 2016 Nov;68(11):2603-2611. (PMID: 27273914)
Pediatrics. 2001 Apr;107(4):E54. (PMID: 11335775)
فهرسة مساهمة: Keywords: Juvenile idiopathic arthritis; Tuberculosis.; Tumor necrosis factor inhibitors.
المشرفين على المادة: 0 (Antirheumatic Agents)
0 (Tumor Necrosis Factor-alpha)
تواريخ الأحداث: Date Created: 20171111 Date Completed: 20180529 Latest Revision: 20181113
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC5679346
DOI: 10.1186/s12969-017-0207-8
PMID: 29121953
قاعدة البيانات: MEDLINE
الوصف
تدمد:1546-0096
DOI:10.1186/s12969-017-0207-8